Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).

Katherine L. Pogue-Geile,Thierry André,Nan Song,Corey Lipchik,Ying Wang,Rim S. Kim,Huichen Feng,Patrick G. Gavin,Jean-Luc Van Laethem,Ashok Srinivasan,Tamas Hickish,Samuel A. Jacobs,Josep Tabernero,Peter C. Lucas,Aimery de Gramont,Norman Wolmark,Jean-François Fléjou,Soonmyung Paik

Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).

2019

Katherine L. Pogue-Geile
Thierry André
Nan Song
Corey Lipchik
Ying Wang
Rim S. Kim
Huichen Feng
Patrick G. Gavin
Jean-Luc Van Laethem
Ashok Srinivasan
Tamas Hickish
Samuel A. Jacobs
Josep Tabernero
Peter C. Lucas
Aimery de Gramont
Norman Wolmark
Jean-François Fléjou
Soonmyung Paik

3503Background: MOSAIC and C-07 showed that oxaliplatin (OX) added to 5-fluorouracil plus leucovorin significantly improved disease free survival (DFS). However, OX is associated with neurotoxicity...

Keywords:

Pathology
Colorectal cancer
Oncology
Oxaliplatin
Adjuvant
Medicine
Internal medicine
Neurotoxicity
disease free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations